Project 1 - Moderna

.docx

School

University of Maryland, University College *

*We aren’t endorsed by this school

Course

110

Subject

Management

Date

May 2, 2024

Type

docx

Pages

8

Uploaded by lococheech on coursehero.com

PROJECT 1- MODERNA 1 Moderna Marcelino Sanchez BMGT 110 Professor Brian White
PROJECT 1-MODERNA 2 Introduction Investing in Moderna, a pioneering biotechnology company at the forefront of mRNA technology, offers a compelling opportunity to participate in groundbreaking advancements in healthcare. With a relentless commitment to innovation and a track record of pioneering research, Moderna has positioned itself as a leader in the development of mRNA-based therapies and vaccines. Amidst global health challenges and increasing demand for transformative medical solutions, investing in Moderna provides investors with exposure to a dynamic and rapidly evolving industry poised for significant growth. By capitalizing on Moderna's innovative pipeline, strategic partnerships, and proven ability to bring novel treatments to market, investors have the potential to not only generate financial returns but also contribute to shaping the future of medicine. Discuss Moderna’s business and purpose Moderna, founded in 2010, is a cutting-edge biotechnology company with a clear mission: to revolutionize medicine through the development of mRNA-based therapies and vaccines. At its core, Moderna is driven by a commitment to harness the potential of messenger RNA (mRNA) technology to address unmet medical needs and improve human health globally. (Vuong, 2023) The business of Moderna revolves around leveraging mRNA, a molecule that carries instructions for cells to produce proteins, to develop a diverse range of therapeutic and preventive solutions. (Moderna, n.d.) Unlike traditional approaches, which often rely on weakened or inactivated pathogens, mRNA vaccines prompt the body's cells to produce specific proteins, triggering an immune response. This innovative approach offers
PROJECT 1-MODERNA 3 several advantages, including faster development timelines, scalability, and potential for customization. Moderna's purpose extends beyond mere profit-making; it seeks to redefine the landscape of medicine by addressing diseases that have eluded traditional treatments. The company's pipeline includes candidates for a wide range of conditions, including infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune disorders. (D, 2023) Notably, Moderna gained widespread attention for its rapid development of mRNA vaccines against COVID-19, showcasing the transformative potential of its technology in combating global health crises. Identify Moderna’s stakeholders Moderna's stakeholders encompass a diverse range of individuals, organizations, and entities crucial to its operations and success: Investors and Shareholders : Including individuals, venture capital firms, and institutional investors who have provided funding to Moderna. They have a significant financial stake in the company's success and closely monitor its performance and growth. Employees : Moderna's workforce, comprising scientists, researchers, engineers, and administrative staff, are vital stakeholders. They contribute their expertise to develop mRNA- based therapies and vaccines. Partners and Collaborators : Moderna collaborates with academic institutions, other biotechnology companies, governments, and non-profit organizations. These partnerships facilitate research, development, and distribution of Moderna's products.
Your preview ends here
Eager to read complete document? Join bartleby learn and gain access to the full version
  • Access to all documents
  • Unlimited textbook solutions
  • 24/7 expert homework help